Quarterly ResultMay 15, 2026, 09:07 AM
Adaptin Bio Q1 Net Loss Widens to $1.15M; Cash $301K
AI Summary
Adaptin Bio reported a significant increase in net loss for Q1 2026, reaching $1.15 million compared to $0.60 million in Q1 2025, driven by higher operating expenses. The company's cash and cash equivalents decreased to $301,309 as of March 31, 2026, from $459,174 at year-end 2025. Management expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional funding. The company also completed secondary and third closings of a follow-on private placement offering and extended the expiration date of certain warrants.
Key Highlights
- Net loss for Q1 2026 was $(1,146,096), up from $(603,084) in Q1 2025.
- Cash and cash equivalents decreased to $301,309 as of March 31, 2026, from $459,174 at December 31, 2025.
- Total operating expenses increased to $1,144,153 in Q1 2026 from $850,458 in Q1 2025.
- Net loss per share was $(0.13) for Q1 2026, compared to $(0.10) for Q1 2025.
- Total stockholders' deficit increased to $(1,775,571) as of March 31, 2026.
- Net cash used in operating activities was $(596,298) in Q1 2026.
- Raised $652,000 gross proceeds from common stock issuance in private placement in Q1 2026.
- A Warrant expiration date extended by six months to September 30, 2026.
Price Impact
More from APTN